Why the study?
Diabetic patients have reduced therapeutic response to clopidogrel after PCI for chronic coronary syndromes.
Does ticagrelor improve platelet inhibition compared to clopidogrel in diabetic patients after recent PCI for chronic coronary syndromes?
Does ticagrelor improve platelet inhibition compared to clopidogrel in diabetic patients after recent PCI for chronic coronary syndromes?
Ticagrelor provides greater platelet inhibition than clopidogrel in diabetic patients following PCI for chronic coronary syndromes, without an apparent increase in short-term bleeding.
Answers are grounded in this paper and cite their sources.
May favor ticagrelor for platelet inhibition in diabetic post-PCI patients without short-term bleeding; extends data to chronic syndromes but remains hypothesis-generating.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: